Table 2.

Multivariate Cox proportional hazards regression analysis of the derived RNA signatures and traditional characteristics with RFS

	mRNA-only signature				Integrated mRNA–lncRNA signature
	Training set		Validation set		Training set		Validation set
Variable^a	HR (95% CI)	P	HR (95% CI)	P	HR (95% CI)	P	HR (95% CI)	P
Age (≤50 y as reference)	1.06 (0.16–6.95)	0.949	1.29 (0.10–16.09)	0.845	1.01 (0.09–11.11)	0.995	1.18 (0.11–12.90)	0.890
Menopause (no as reference)	0.67 (0.12–3.73)	0.646	0.43 (0.03–5.77)	0.521	0.63 (0.07–5.38)	0.672	0.56 (0.05–6.18)	0.635
Tumor grade (≤II as reference)	1.61 (0.40–6.45)	0.501	0.71 (0.10–5.00)	0.729	1.79 (0.44–7.31)	0.416	0.91 (0.14–6.09)	0.920
Tumor size (≤2 cm as reference)	1.13 (0.34–3.70)	0.846	4.45 (0.48–41.47)	0.189	0.78 (0.20–2.99)	0.712	4.72 (0.51–43.68)	0.171
Positive LNs (≤3 as reference)	1.95 (0.53–7.24)	0.319	2.48 (0.53–11.53)	0.247	2.37 (0.61–9.16)	0.211	3.38 (0.70–16.31)	0.130
Radiotherapy (no as reference)	4.03 (0.93–17.39)	0.062	3.87 (0.64–23.49)	0.141	3.79 (0.83–17.31)	0.086	3.58 (0.63–20.33)	0.151
Chemotherapy (non-taxane as reference)	0.49 (0.15–1.57)	0.228	1.22 (0.25–5.95)	0.804	0.69 (0.17–2.74)	0.593	1.41 (0.27–7.26)	0.683
Signature (low-risk as reference)	4.46 (1.34–14.91)	0.015	6.31 (1.20–33.26)	0.030	10.00 (2.53–39.47)	0.001	14.04 (1.56–126.71)	0.019

Abbreviation: LN, lymph node.

↵^aAdjusted by Cox proportional hazards models including age, menopausal status, tumor grade, tumor size, positive lymph nodes, radiotherapy, chemotherapy, and integrated RNA signature.